Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company developing
potentially life-changing treatments for cancer and other serious diseases,
this morning announced that the company’s chairman and chief executive officer
Rodney Varner will be leading a presentation and answering questions from
investors at the third annual LD Micro Virtual Conference. The company’s
presentation is scheduled to take place on Wednesday, March 4 at 1:40 PM EST.
The conference will showcase over 40 companies in the small/micro-cap space and
will be held via webcast. “We are delighted to be hosting our third virtual
event in order to showcase some of the truly unique names in micro-cap,” “There
are many people and companies who are unable to attend our live events due to
any number of reasons, so we are happy to offer an additional way for companies
to present to investors without taking a lot of time out of their day-to-day
operations. While virtual events will never replace the experience of sitting
in the same room as other humans, it is a great format for updating the
investor community and getting increased exposure,” LD Micro president Chris
Lahiji stated in the news release.
To access the live presentation, visit http://ibn.fm/vO2NI
To view the full press release, visit http://ibn.fm/4FzMv
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing treatments for cancer and other serious
diseases. Genprex’s technologies are designed to administer disease-fighting
genes to provide new treatment options for large patient populations with
cancer and other serious diseases who currently have limited treatment options.
Genprex works with world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches for patients with cancer and other serious
diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy
for non-small cell lung cancer (“NSCLC”), uses the company’s unique,
proprietary platform which delivers cancer-fighting genes by encapsulating them
into nanoscale hollow spheres called nanovesicles, which are then administered intravenously
and taken up by tumor cells where they express proteins that are missing or
found in low quantities. In January 2020, the FDA granted Fast Track
Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the
treatment of NSCLC. For more information, please visit the company’s website
at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment